Highest-materiality recent filing
P&G Q3 net sales +7% to $21.2B, core EPS $1.59; guides toward lower end of FY range
Net sales $21.2B (+7%), organic sales +3% driven by 2% volume growth and 1% pricing.
P&G Q3 FY2026 organic sales +3%, core EPS $1.59, guidance maintained
Organic sales +3% (volume +2%, price +1%); 10 of 10 categories and 7 of 7 regions grew.
P&G Q2 FY2026: Net sales +1% to $22.2B, core EPS flat at $1.88, maintains FY guidance
Diluted EPS $1.78 (-5% YoY); core EPS $1.88 (flat); organic sales unchanged.
P&G Q2 FY26: organic sales flat, core EPS $1.88, guidance maintained
Q2 organic sales +0% (volume -1%, pricing +1%); core EPS $1.88, in-line with prior year.
P&G Health Care CEO Jennifer Davis to retire June 30, 2026
Jennifer Davis, CEO - Health Care, notified P&G on Dec 9, 2025 of retirement effective June 30, 2026.
P&G Q1 FY2026: net sales $22.4B (+3%), diluted EPS $1.95 (+21%), core EPS $1.99 (+3%)
Organic sales +2%; volume neutral, pricing +1%, mix +1%. Beauty organic sales +6%, Grooming +3%.
P&G Q1 FY2026: organic sales +2%, core EPS $1.99 (+3% YoY); reaffirms guidance
Q1 organic sales +2% (flat volume, +1% pricing, +1% mix); core EPS $1.99 (+3% YoY); adjusted free cash flow 102%.
P&G reports Q4 FY2025 net sales +2% to $20.9B, diluted EPS +17% to $1.48; FY2025 EPS $6.51 +8%
FY2025 net sales $84.3B (flat YoY), organic sales +2%; diluted EPS $6.51 (+8%), core EPS $6.83 (+4%).
P&G Q4 FY2025 organic sales +2%, core EPS +6%; FY2026 guidance core EPS growth 0-4%
FY2025 organic sales +2% (vol +1%, price +1%); core EPS $6.83 (+4% YoY); adj. free cash flow productivity 87%.
Shailesh Jejurikar, age 58, currently COO, will succeed Jon Moeller as President and CEO effective January 1, 2026.
P&G announces 2-year restructuring; to cut up to 7,000 roles, record $1.0-1.6B charge
Program includes portfolio choices (brand exits in certain markets), supply chain optimization, and organization design.
P&G Q3 net sales $19.8B down 2%; organic sales +1%; EPS $1.54; cuts FY sales outlook
Net sales $19.8B, -2% YoY; organic sales +1% on higher pricing; diluted EPS $1.54 (+1%).
P&G Q3 organic sales +1%; cuts FY25 core EPS growth outlook to 2-4%
Q3 organic sales +1% (volume flat, price +1%); core EPS $1.54, +1% YoY; currency-neutral core EPS +3%.
P&G declares quarterly dividend of $1.0568, a 5% increase, payable May 15
Quarterly dividend raised 5% to $1.0568 per share from prior $1.0065.
P&G Q2 net sales $21.9B (+2%), organic +3%; core EPS $1.88 (+2%); maintains FY guidance
Q2 net sales $21.9B, +2% YoY; organic sales +3% on +2% volume and +1% favorable mix.
P&G Q2 FY2025 organic sales +3%, core EPS $1.88; FY guidance maintained
Organic sales +3% YoY; organic volume +2%; core EPS $1.88 (+2% YoY, +3% currency neutral)
P&G Q1 FY2025: core EPS +5% to $1.93, organic sales +2%; maintains FY guidance
Net sales $21.7B (-1% YoY); organic sales +2% driven by +1% pricing and +1% organic volume.
P&G Q1 FY2025 organic sales +2%, core EPS $1.93 (+5%); maintains FY guidance
Organic sales grew 2% (volume +1%, pricing +1%), 8 of 10 categories grew organic sales.
P&G Q4 net sales flat, organic +2%, core EPS +2%; FY24 organic +4%, core EPS +12%
Q4 net sales $20.5B (unchanged YoY); organic sales +2% on volume +2%, price +1%.
P&G Q4 FY2024 organic sales +2%, core EPS +2%; FY2025 guidance: organic sales +3-5%
FY2024 full year: organic sales +4%, core EPS +12%, adjusted FCF productivity 105%.
P&G Q3 FY2024 EPS $1.52 (+11% YoY); raises core EPS growth guidance to 10-11%
Net sales $20.2B (+1% YoY); organic sales +3% on higher pricing.
P&G Q3 FY2024 core EPS $1.52 beats; organic sales +3%; raises FY core EPS growth outlook to +10-11%
Q3 diluted EPS $1.52 (up 11% YoY); core EPS $1.52; currency-neutral core EPS $1.61 (+18% YoY).
P&G raises quarterly dividend 7% to $1.0065; payable May 15, 2024
New quarterly dividend of $1.0065 per share, a 7% increase from the prior quarter.
P&G Q2 Core EPS $1.84 +16% YoY, raises FY Core EPS guidance to 8-9% growth
Net sales $21.4B (+3% YoY); organic sales +4% driven by +4% pricing, -1% volume.
P&G Q2 FY24 Core EPS $1.84, up 16% YoY; Organic sales growth 4%
Core EPS of $1.84, up 16% YoY; diluted EPS $1.40 includes $1.3B pre-tax Gillette impairment.
P&G to take $2.0-2.5B after-tax charges: restructuring ($1.0-1.5B) plus Gillette impairment ($1.0B)
Restructuring charges of $1.0-1.5B after-tax (mostly noncash) in FY2024/25 from exiting certain Enterprise Markets (Argentina, Nigeria).
P&G Q1 FY24 net sales $21.9B (+6%), EPS $1.83 (+17%) beat
Diluted EPS $1.83, up 17% YoY; core EPS also $1.83, up 17%.
PG Q1 FY24: EPS $1.83 beat, organic sales +7%, FY24 organic outlook +4-5%
Q1 diluted EPS $1.83 (up 17% YoY); Core EPS $1.83; Currency-neutral Core EPS $1.90 (+21%).
On June 9, 2025, the Board of Directors of The Procter & Gamble Company (the “Company”) appointed Craig Arnold, former Chairman and Chief Executive Officer of Eaton Corporation, as a Director of the Company, effective June 9.
On April 9, 2024, Angela F. Braly notified The Procter & Gamble Company (the “Company”) of her decision to retire from the Company’s Board of Directors effective June 11, 2024.
On December 12, 2023, the Board of Directors of The Procter & Gamble Company (the “Company”) appointed Ashley McEvoy, former Executive Vice President, Worldwide Chairman of MedTech at Johnson & Johnson, as a Director of the Company, effective December 12.
On April 11, 2023, the Board of Directors of The Procter & Gamble Company (the “Company”) appointed Sheila Bonini, Senior Vice President – Private Sector Engagement for World Wildlife Fund, Inc., and Robert Portman, former United States Senator, as Directors of the Company, effective April 11, 2023.
On April 11, 2023, the Board of Directors of The Procter & Gamble Company (the “Company”) appointed Sheila Bonini, Senior Vice President – Private Sector Engagement for World Wildlife Fund, Inc., and Robert Portman, former United States Senator, as Directors of the Company, effective April 11, 2023.
Jon R. Moeller, currently President and Chief Executive Officer and a member of the Board of Directors (“the Board”), has been appointed Chairman of the Board, in addition to his current responsibilities, effective July 1, 2022.
David S. Taylor, Executive Chairman of the Board, will retire from the Company, effective June 30, 2022.
On January 7, 2022, Michael G. Homan, currently Senior Vice President – Chief Accounting Officer, announced his intention to retire from The Procter & Gamble Company (the “Company”) after 24 years of service, effective July 31, 2022.
Accordingly, on January 7, 2022, the Company’s Board of Directors designated Matthew W. Janzaruk (age 48), currently Vice President – Finance & Accounting, Global Internal Audit, as the Company’s principal accounting officer, effective March 1, 2022.
Ms. Whitman has notified the Company of her intent to resign from the Company’s Board of Directors, effective upon Senate confirmation of her appointment.
On August 4, 2021, Nelson Peltz notified The Procter & Gamble Company (the "Company") of his intention to conclude his service on the Company's Board of Directors at the end of his current term, which expires at the Company's upcoming annual meeting of shareholders, expected to be held on October 12, 2021.
Mr. Moeller has also been appointed as a member of the Company’s Board of Directors, effective immediately.
Max materiality 0.90 · Median 0.60 · Most common event earnings